Pre-operative magnetic resonance imaging can predict prostate cancer with risk for positive surgical margins

M. Quentin1·L. Schimmöller1·T. Ullrich1·B. Valentin1·D. Demetrescu1·R. Al-Monajjed2·D. Mally2·I. Esposito3·P. Albers2·G. Antoch1·C. Arsov2

Received: 25 December 2021 / Revised: 21 April 2022 / Accepted: 26 April 2022 / Published online: 16 May 2022
© The Author(s) 2022

Abstract

Purpose Analysis of patients with pre-operative 3 T multiparametric prostate MRI (mpMRI) to determine reliable MRI-based risk predictors of patients at risk for positive surgical margins (PSM) in robotic assisted radical prostatectomy (RPE).

Methods Consecutive patients with 3 T mpMRI and subsequent RPE from 01/2015 to 12/2018 were retrospectively included. Patients were compared regarding clinical and MRI related parameters such as length of capsular tumor contact (LCC) and distance to the membranous urethra (UD).

Results Forty-nine of 179 patients (27%) had PSM in 70 different localizations, with the majority located at the capsule (57%, 40/70), mostly apical and/or posterior. The second most often PSM occurred at the apical urethra (22%, 15/70). PCA was visible on mpMRI at the localization of PSM in 93% at the capsule and in 80% at the urethra. PSA, PI-RADS classification, extraprostatic extension (EPE), and seminal vesicles infiltration (SVI) on MRI were significantly higher / more frequent in patients with PSM. LCC (AUC 0.710), EPE (AUC 0.693), and UD (1-AUC 0.673) predicted PSM (overall). An UD of ≤ 3.5 mm showed the highest accuracy of 95% (J = 0.946) for PSM at the urethra and a LCC of ≥ 22.5 mm with 77% (J = 0.378) for PSM at the capsule.

Conclusion PSM occurred mostly in the apex and/or posteriorly at the capsule or at the apical urethra. LCC was the best MRI predictor for PSM at the capsule and UD for tumors with PSM at the apical urethra. Using these MRI parameters readers might pre-operatively determine PCA localizations at risk for PSM.

Keywords Prostate cancer · Prostate MRI · Staging · Prostatectomy · Positive surgical margins · Predictive biomarker
Abbreviations
LCC  Length of capsular tumor contact
EPE  Extraprostatic extension
mpMRI  Multiparametric prostate MRI
PCA  Prostate cancer
PI-RADS  Prostate Imaging Reporting and Data System
PSM  Positive surgical margins
SVI  Seminal vesicle infiltration
UD  PCA distance to the membranous urethra

Introduction
Multiparametric prostate MRI (mpMRI) plays an increasingly significant role in prostate cancer (PCA) diagnostics. Various studies showed that mpMRI is highly sensitive in visualization of PCA suspect lesions and targeted MR-guided biopsy better predict the correct Gleason score on radical prostatectomy (RPE) [1, 2]. Apart from the detection, mpMRI comprises various staging information and is currently seen as the best available imaging tool for assessing extraprostatic extension (EPE) and the T-stage [3–5]. Urologic assessment to predict nonorgan-confined PCA was limited to nomograms based on biopsy results [6]. Meta-analysis showed a moderate sensitivity of 61% of MRI to detect EPE (overall stage T3 disease) with high specificity of 88%, but at 3 Tesla (3 T) MRI also sensitivities above 70% are reported [3, 4]. Over the last year’s positron emission tomography (PET) with a prostate specific membrane antigen (PSMA) tracer got higher priority focusing primarily biochemical PCA recurrence and/or M and N staging in high-risk PCA [7–9]. Additional improvement might be achieved by PSMA-PET/MRI and/or artificial intelligence, respectively radiomics [10]. The European Association of Urology (EAU) Guidelines recommend to use pre-biopsy mpMRI for local staging [11].

Aim of this study was to analyze 3 T mpMRI examinations of patients with subsequent RPE to determine reliable MRI-based risk predictors to identify patients at risk for PSM. Therefore, PCA visibility in PSM localization, length of capsular contact (LCC), EPE, distance to the membranous urethra (UD), and tumor infiltration in other structures was analyzed. The results are supposed to help radiologists to focus on relevant risk predictors and to help urologists with pre-operative planning to avoid PSM.

Materials and methods
Study design
We retrospectively analyzed all consecutive patients from January 2015 to December 2018 with in-house robotic assisted RPE and prior mpMRI for PCA detection (n = 179) in this single-center cohort study. We did not include patients without or incomplete mpMRI (Supp. Fig. S1). None of the patients had received prior treatment for PCA. The study was approved by the local Independent Ethics Committee (IEC) (Study number: 2018-227-RetroDEuA; Medical Faculty, University Dusseldorf).

Imaging
The mpMRI of the prostate was performed on a 3 T MRI scanner (Magnetom TIM Trio™, Prisma™ or Skyra™; Siemens Healthineers) with 18 or 60 channel phased-array surface-coils plus/minus 32 channel spine coil according to the European Society of Urogenital Radiology (ESUR) guidelines and the national recommendations [16, 17]. The MR protocol contained T1-weighted images (from the whole pelvis), T2-weighted images (in 3 planes, 3 mm slice thickness), diffusion-weighted images (3 mm slice thickness, b-values: 0, 500, 1000 s/mm² for ADC calculation, an additional high b-value ≥ 1400 s/mm²), and dynamic contrast-enhanced images (DCE; 3 mm slice thickness, scan time 3 min, temporal resolution < 9 s). The detailed MR-protocol has been published previously [18]. All patients received butylscopolamine (20 mg Buscopan®, Boehringer Ingelheim Pharma) to suppress bowel peristalsis.

Image analysis
The mpMRI was retrospectively analyzed by two experienced, board-certified radiologists in consensus subspecialized in prostate MRI (M.Q. and LS, both with more than 10 years’ experience in reading prostate MRI) regarding the following aspects in relation to the histopathologic examination of the prostatectomy specimens (localization of positive surgical margins): visible PCA, extraprostatic extension.
(EPE), length of capsular tumor contact (LCC), PCA distance to the membranous urethra (UD), and seminal vesicle infiltration (SVI). All measurements were performed on high resolution coronary, sagittal, and/or axial T2-weighted images using the plane that showed the lesion best with reference to DWI (ADC map and high b-value images) and DCE. EPE was defined as extension of the tumor beyond the gland boundary (in mm). LCC was determined by the greatest capsular tumor contact in the different planes using curvilinear measurements along the capsule (in mm). UD was defined as shortest distance of the tumor to the proximal membranous urethra, located between the apex of the prostate and the bulb of the corpus spongiosum, extending through the urogenital diaphragm (in mm). SVI was evaluated if the tumor showed a measurable infiltration of the SV (in mm). PI-RADS classification was performed retrospectively in consensus using PI-RADS version 2.1. Radiologists were blinded to clinical parameters especially PCA aggressiveness, tumor stage, and PSA values.

**Prostatectomy**

Robotic assisted radical prostatectomy (RPE) was performed with a 3-arm Da Vinci Surgical Si System (Intuitive Surgical) by three different board-certified surgeons (with each more than 10 years’ experience) and a transperitoneal access. The decision for curative surgery, as well as decisions for lymph node dissection, was made according to the guidelines of the European Association of Urology [11]. Histopathology was performed according to the recommendations of the International Society of Urological Pathology (ISUP).

**Statistical analysis**

Descriptive statistics were used to present patient characteristics. Statistical analyses were performed using IBM SPSS® Statistics (Version 21, IBM Deutschland GmbH). Data are expressed as mean ± SD and median ± IQR. Non-parametric Mann–Whitney-U test was used to compare the group of patients with and without PSM. Statistical significance was defined as a $p$-value < 0.05. Receiver operating characteristic (ROC) analyses were used for quantifying the impact of clinical and MRI related predictors. Youden index ($J = sensitivity + specificity − 1$) was used to measure the clinical diagnostic ability of LCC and UD.

**Results**

**Study population**

From 179 included patients, 49 patients had PSM (R1) in at least one localization. The time between MRI and RPE was in mean $12 ± 7.3$ weeks. PSA was significantly higher in patients with PSM compared to patients without PSM (Table 1). Clinical and postoperative parameters showed limited ability to assess the risk of PSM: age (AUC 0.507; $p = 0.879$), prostate volume (AUC 0.549; $p = 0.315$), PSAD

### Table 1 Patient baseline characteristics

|                       | NSM   | PSM   | $P$-value* |
|-----------------------|-------|-------|------------|
| **Clinical data**     |       |       |            |
| Patients; number      | 130   | 49    |            |
| Age in y; mean ± SD   | 66 ± 8.08 | 66 ± 7.95 | 0.879   |
| PSA value in ng/ml;   |       |       |            |
| median (IQR)          | 8.84 (6.29 – 12.79) | 11 (7.60 – 15.17) | 0.006   |
| PSAD in ng/ml/cm³;    |       |       |            |
| median (IQR)          | 0.23 (0.15 – 0.37) | 0.27 (0.22 – 0.40) | 0.046   |
| Prostate volume in ml;|       |       |            |
| median (IQR)          | 36 (29 – 51) | 38 (32 – 50) | 0.315   |
| ISUP; post-biopsy     |       |       |            |
| median (IQR)          | 2 (2 – 3.75) | 2 (2 – 4) | 0.239   |
| **RPE**               |       |       |            |
| ISUP; post-surgery    |       |       |            |
| median (IQR)          | 2 (2 – 3) | 3 (2 – 4) | 0.031   |
| T2a-c, % (n)          | 65% (85) | 35% (17) | < 0.001  |
| T3a, % (n)            | 22% (28) | 24% (12) |         |
| T3b, % (n)            | 13% (17) | 41% (20) |         |

*Mann–Whitney-U test*

NSM negative surgical margins, PSM positive surgical margins, PSA prostate specific antigen, PSAD prostate specific antigen density, ISUP International Society of Urological Pathology Grade Group

Bold values indicate $P$-value < 0.05
Table 2  Characterization of lesions with positive surgical margins (PSM)

| PSM localization | Side | Left | Right | Both |
|------------------|------|------|-------|------|
| Capsule          | All  | 39%  | 24%   | 37%  |
|                  | Basal| 57%  | 18%   | 27%  |
|                  | Midgl| 55%  | 35%   | 43%  |
|                  | Apical| 55%  | 22%   | 22%  |
|                  | Anterior| 55%  | 35%   | 43%  |
|                  | Posterior| 55%  | 22%   | 22%  |
|                  | Lateral| 55%  | 22%   | 22%  |

| MRI visible PCA in PSM localization | Capsule | all | LCC 23 ± 12.5 mm (mean ± SD) | EPE | EPE 4.4 ± 2.1 mm (mean ± SD) |
|------------------------------------|---------|-----|-------------------------------|-----|-------------------------------|
| Urethra, apical                    | 22%     | 93% | 68% (25/37)                   |     |                               |
| SV                                 | 14%     |     |                               |     |                               |
| Bladder neck                       | 7%      |     |                               |     |                               |

*PSM positive surgical margins, RPE radical prostatectomy, SV seminal vesicles, EPE extraprostatic extension, LCC length of capsular contact of tumor

Table 3  MRI prediction parameters for positive surgical margins (PSM)

| MRI prediction parameters | NSM | PSM | P-value* |
|---------------------------|-----|-----|----------|
| PI-RADS v2.1% (n)         |     |     | 0.002    |
| 3                         | 3%  | 2%  |          |
| 4                         | 43% | 18% |          |
| 5                         | 54% | 80% |          |
| cT3% (n)                  |     |     | 0.040    |
| 72% (107/130)             | 94% | (46/49) |        |
| EPE % (n)                 |     |     | < 0.001  |
| 18% (24/130)              | 57% | (28/49) |        |
| EPE in mm; median (IQR)   |     |     | < 0.001  |
| 3 mm (2 – 5)              | 4 mm | (3 – 6) |        |
| SVI % (n)                 |     |     |          |
| 9% (12/130)               | 37% | (18/49) |        |
| SVI in mm; median (IQR)   |     |     |          |
| 7 mm (5.25 – 11)          | 8 mm | (6 – 11) |        |

Index lesion Localization

| Localization | basal | 27% (35/130) | 29% (14/49) | 0.235 |
|--------------|-------|--------------|-------------|-------|
| midgl        | 33%   | (43/130)     | 45% (22/49) |       |
| apical       | 40%   | (52/130)     | 26% (13/49) | 0.143 |
| anterior     | 30%   | (39/130)     | 37% (18/49) |       |
| posterior    | 34%   | (44/130)     | 41% (20/49) |       |
| lateral      | 36%   | (47/130)     | 22% (11/49) |       |

LCC in mm; median (IQR)

| 12 (8 – 18) | 20 (13 – 26) | < 0.001 |

Cases with PSM at the capsule: 22 (14 – 28)

UD in mm; median (IQR)

| 15 (12 – 27) | 8 (3 – 15) | < 0.001 |

Cases with PSM at the urethra: 2 (1 – 3)

*Mann–Whitney-U test

NSM negative surgical margins, PSM positive surgical margins, EPE extraprostatic extension, SVI seminal vesicle infiltration, LCC length of capsular contact of tumor, UD distance to the membranous urethra, cT3 clinical T3 stage

Bold values indicate P-value < 0.05
(AUC 0.597; \( p = 0.05 \)), PSA (AUC 0.633; \( p = 0.006 \)), ISUP grade in biopsy (AUC 0.554; \( p = 264 \)), ISUP grade after prostatectomy (AUC 0.597; \( p = 0.05 \)), with postoperative T-stage being the best parameter (AUC 0.681; \( p < 0.001 \)).

**Characterization of PSM**

PSM were documented in 70 different localizations. The majority of PSM (57%) were located at the capsule, and therein mostly apical and posteriorly (Table 2). The apical urethra was the most infiltrated structure (22%). MpMRI showed a high ability to visualize PCA at the localization of PSM, ranging from 80% at the urethra to 100% at the bladder neck. In 6 patients with PSM the tumor was invisible on mpMRI in the following localizations: 3 at the capsule, one at the seminal vesicles, and in 2 patients at the urethra.

**Prediction of PSM**

PI-RADS scores were significantly higher in patients with PSM. Also, extraprostatic extension and seminal vesicles infiltration on MRI was significantly more frequent in patients with PSM (Table 3). Index lesions of these patients had a significant higher LCC and a significant lower UD. LCC was the best MRI parameter to predict PSM (AUC 0.710). AUC values for the other MRI parameters were as follows: EPE 0.693, UD 0.327, SVI 0.638, PI-RADS 0.627, and cT3 stage 0.562 (Fig. 1). In the cases with PSM at the apical urethra 1-AUC for UD was 0.981 (\( p < 0.001 \)). A UD ≤ 3.5 mm showed highest accuracy with a sensitivity of 100% and specificity of 95% (\( J = 0.946 \)) for PSM; a LCC of ≥ 22.5 mm with a sensitivity of 49% and specificity of 89% (\( J = 0.378 \)) for PSM at the capsule (Figs. 2, 3 and 4).

**Discussion**

MpMRI (3 T) showed a high ability to visualize PCA at the localization of PSM, which occurred mostly apical and/or posteriorly at the capsule or at the apical urethra. In 6 patients with PSM the tumor was invisible on mpMRI. 35% of patients with PSM had organ-confined PCA. Best clinical parameter to predict PSM was the postoperative T-stage. LCC was the best MRI predictor for PSM at the capsule, which performed better than the clinical parameters. Nevertheless, in tumors with PSM at the apical urethra, UD was the best MRI parameter. Highest accuracy was documented for UD ≤ 3.5 mm, indicating a high risk for PSM at the urethra and for LCC ≥ 22.5 mm, indicating a high risk for PSM at the capsule. Using these MRI parameters PCA localizations at risk for PSM might be pre-operatively determined.

Park et al. developed and validated a scoring system for MRI to predict PSM inducing the PI-RADS score, tumor location on posterolateral side or at the apex, and length of capsular contact, archiving an AUC value of 0.80 [19]. Compared to our results the score was slightly better than LCC alone, but inferior to UD for apical tumors. There are some aspects of this score that needs to be discussed. First, PI-RADS score was weighted more heavily compared to tumor localization. Second, PI-RADS category 3 (clinically significant cancer is equivocal) and PI-RADS category 4 (clinically significant is likely to be present) have the same impact on the score, although in clinically consequence is different. Third, capsular contact ≤ 14 mm was rated with 0. Other studies showed that the risk for EPE was already increased at LCC ≥ 11 mm [4]. Main limitation is that risk factors for PSM depend on the localization of PSM and therefore should be assessed separately for either risk of PSM at the apical urethra or at the capsule.

The diagnostic performance of mpMRI is influenced by the different prevalence of EPE in different risk stratified cohorts [20]. High negative predictive values (88%) are only reached in low-risk cohorts, where patients could benefit if...
they were selected for nerve sparing surgery by the prior mpMRI. Positive predictive value was highest (89%) in high-risk cohort, which could help to reduce the risk of PSM. In a prospective randomized single-center trial preoperative MRI could only reduce PSM in low-risk PCA [21]. According to the authors a main limitation is lacking communication

Fig. 2 ROC analysis of LCC as predictor for PSM at the capsule and UD as predictor for positive surgical margin (PSM) at the apical urethra. LCC length of capsular contact of tumor, UD PCA distance to the membranous urethra

Fig. 3 Patient with organ-confined prostate cancer (T2c) and positive surgical margins at the apical urethra with broad tumor contact to the anterior circumference of the apical urethra on mpMRI. PCA distance to the membranous urethra (UD) was 2 mm (arrows). Upper left: T2 axial, upper right: DCE lower left, T2 coronal, lower right: T2 sagittal
between radiologists and urologists, which is crucial to adopt surgical approaches.

A recent meta-analysis showed that mpMRI had a considerable impact on the extent of resection during RPE, but modifications of neuro-vascular-bundle preservation did not influence PSM rates [22]. However, apart from relatively small number of studies, mostly retrospective design, different MRI protocols, scanner, and field strength, a further reason for these results might be the lack of standardized MRI reading.

This study is limited by the retrospective design and the single-center evaluation. Although PCA is usually a slow growing tumor, the time interval between MRI and operation might have influenced the results. MRI was acquired at 3 T scanners and reading was performed by subspecialized experts in consensus, but we did not access interreader variability, so less experienced readers may perform differently. Furthermore, PSM at the capsule and at the urethra may have different clinical impact, therapeutic consequence, and risk for biochemical recurrence (BCR). However, this study focuses on the MRI visibility and prediction of PSM.

In conclusion, mpMRI (3 T) was an excellent tool to visualize PCA and could help to identify patients at risk for PSM, which occurs mostly apical and/or posteriorly at the capsule or at the apical urethra. Best predictive parameters were LCC at the capsule and UD for apical located tumors. Since communication with the surgeon is crucial to adopt the surgical strategy, EPE, LCC and UD should be highlighted in the structured report.

**Supplementary Information** The online version contains supplementary material available at https://doi.org/10.1007/s00261-022-03543-z.

**Acknowledgements** None.

**Author contributions** Conceptualization: QM, SL, AC, Data curation: QM, SL, DD, MD, EI, AC, Formal analysis: QM, SL, UT, Investigation: SL, UT, VB, MD, EI, Methodology: QM, SL, AC, Project administration: SL, AP, AG, Resources: MD, EI, AP, AG, Software: VB, AR, Supervision: QM, SL, EI, AP, AG, AC, Validation: QM, SL, DD, EI, AG, AC, Visualization: QM, SL, VB, DD, MR, Writing-original draft: QM, SL, Writing-review & editing: SL, UT, AP, AG, AC.

**Funding** Open Access funding enabled and organized by Projekt DEAL.
Declarations

Conflict of interest There is no conflict of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. [1] Thompson JE, Van Leeuwen PJ, Moses D, et al (2016) The diagnostic performance of multiparametric magnetic resonance imaging to detect significant prostate cancer. J Urol 195:1428–1435. https://doi.org/10.1016/j.juro.2015.10.140
2. Arsov C, Becker N, Rabenalt R, et al (2015) The use of targeted MR-guided prostate biopsy reduces the risk of Gleason upgrading on radical prostatectomy. J Cancer Res Clin Oncol 141:2061–2068. https://doi.org/10.1007/s00432-015-1991-5
3. [3] de Rooij M, Hamoen EHI, Witjes JA, et al (2016) Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol 70:233–245. https://doi.org/10.1016/j.euro.2015.07.029
4. Valentin B, Schimmöller L, Ullrich T, et al (2021) Magnetic resonance imaging improves the prediction of tumor staging in localized prostate cancer. Abdom Radiol 46:2751–2759. https://doi.org/10.1007/s00261-020-02913-9
5. [5] Valentin B, Arsov C, Ullrich T, et al (2022) Comparison of 3 T mpMRI and pelvic CT examinations for detection of lymph node metastases in patients with prostate cancer. Eur J Radiol 147:110110. https://doi.org/10.1016/j.ejrad.2021.110110. Epub 2021 Dec 17.
6. [6] Pepe P, Fraggetta F, Galia A, et al (2008) Is Quantitative Histologic Examination Useful to Predict Nonorgan-Confined Prostate Cancer When Saturation Biopsy Is Performed? Urology 72:. https://doi.org/10.1016/j.urology.2008.05.045
7. [7] Abrams-Pompe RS, Fanti S, Schoots IG, et al (2021) The Role of Magnetic Resonance Imaging and Positron Emission Tomography/Computed Tomography in the Primary Staging of Newly Diagnosed Prostate Cancer: A Systematic Review of the Literature. Eur Urol Oncol 4:370–395. https://doi.org/10.1016/j.euo.2020.11.002
8. [8] Zhou C, Tang Y, Deng Z, et al. (2022) Comparison of 68GaPSMA PET/CT and multiparametric MRI for the detection of low- and intermediate-risk prostate cancer. EJNMMI Res 12(1):10. https://doi.org/10.1186/s13550-022-00881-3.
9. [9] Mazrani W, Cook GJR, Bomanji J (2022) Role of 68Ga and 18F PSMA PET/CT and PET/MRI in biochemical recurrence of prostate cancer: a systematic review of prospective studies. Nucl Med Commun. https://doi.org/10.1097/NMN.0000000000001557.
10. [10] Solari EL, Gafita A, Schachoff S, et al. (2022) The added value of PSMA PET/MR radiomics for prostate cancer staging. Eur J Nucl Med Mol Imaging 49(2):527-538. https://doi.org/10.1007/s00259-021-05430-z
11. [11] Mottet N, van den Bergh RCN, Briers E, et al (2021) EAU-ESTRO-ESUR-SIOL Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol 79:243–262. https://doi.org/10.1016/j.euro.2020.09.042
12. [12] Petralia G, Musi G, Padhani AR, et al (2015) Robot-assisted Radical Prostatectomy: Multiparametric MR Imaging—directed Intraoperative Frozen-Section Analysis to Reduce the Rate of Positive Surgical Margins. Radiology 274:. https://doi.org/10.1148/radiol.141140044
13. [13] Chuang AY, Epstein JJ (2008) Positive surgical margins in areas of capsular incision in otherwise organ-confined disease at radical prostatectomy: Histologic features and pitfalls. Am J Surg Pathol 32:1201–1206. https://doi.org/10.1097/PAS.0b013e318162a8bf
14. [14] Yossepowitch O, Briganti A, Eastham JA, et al (2014) Positive surgical margins after radical prostatectomy: a systematic review and contemporary update. Eur Urol 65:303–13. https://doi.org/10.1016/j.euro.2013.07.039
15. [15] McEvoy SH, Raeside MC, Chaim J, et al (2018) Preoperative prostate MRI: A road map for surgery. Am J Roentgenol 211:383–391. https://doi.org/10.2214/AJR.17.18757
16. [16] Barentsz JO, Richenberg J, Clements R, et al (2012) ESUR prostate MR guidelines 2012. Eur Radiol 22:746–757. https://doi.org/10.1007/s00330-011-2377-y
17. [17] Franiel T, Quentin M, Mueller-Lisse UG, et al. (2017) MRT der Prostata: Empfehlungen zur Vorbereitung und Durchführung. RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebung Verfahren 189:21–28. https://doi.org/10.1055/s-0042-119451
18. Schimmöller L, Quentin M, Arsov C, et al (2014) MR-sequences for prostate cancer diagnostics: validation based on the PI-RADS scoring system and targeted MR-guided in-bore biopsy. Eur Radiol 24:2582–2589. https://doi.org/10.1007/s00330-014-3276-9
19. [19] Park MY, Park KJ, Kim M hyun, Kim JK (2021) Preoperative MRI-based estimation of risk for positive resection margin after radical prostatectomy in patients with prostate cancer: development and validation of a simple scoring system. Eur Radiol 31:. https://doi.org/10.1007/s00330-021-06456-1
20. [20] Somford DM, Hamoen EH, Füttnerer J, et al (2013) The predictive value of endorectal 3 tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol 190:1728–1734. https://doi.org/10.1016/j.juro.2013.05.021
21. [21] Rud E, Baco E, Klotz D, et al (2015) Does Preoperative Magnetic Resonance Imaging Reduce the Rate of Positive Surgical Margins at Radical Prostatectomy in a Randomised Clinical Trial? Eur Urol 68:487–496. https://doi.org/10.1016/j.euro.2015.02.039
22. [22] Kozikowski M, Malewski W, Michalak W, Dobruch J (2019) Clinical utility of MRI in the decision-making process before radical prostatectomy: Systematic review and meta-analysis. PLoS One 14:e0210194. https://doi.org/10.1371/journal.pone.0210194

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.